专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2005107727A1 STEROID INTRAOCULAR IMPLANTS HAVING AN EXTENDED SUSTAINED RELEASE FOR A PERIOD OF GREATER THAN TWO MONTHS 审中-公开
标题翻译：具有超过两个月的延长的持续释放的STEROID手术植入物
公开(公告)号：WO2005107727A1
公开(公告)日：2005-11-17
申请号：PCT/US2005/015113
申请日：2005-04-28
申请人： ALLERGAN, INC. , HUANG, Glenn, T. , NIVAGGIOLI, Thierry , SPADA, Lon, T. , SUGIMOTO, Hiroshi , BLANDA, Wendy, M. , CHANG, James, N. , OLEJNIK, Orest
发明人： HUANG, Glenn, T. , NIVAGGIOLI, Thierry , SPADA, Lon, T. , SUGIMOTO, Hiroshi , BLANDA, Wendy, M. , CHANG, James, N. , OLEJNIK, Orest
IPC分类号： A61K31/00
CPC分类号： A61K9/0051 , A61K9/0092 , A61K31/573 , A61K31/58 , A61K45/06 , A61K2300/00
摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.
摘要翻译：生物相容性眼内植入物包括彼此相关的类固醇和聚合物，以促进类固醇进入眼睛大于约两个月的时间。类固醇可以与可生物降解的聚合物基质相关联，例如两种可生物降解聚合物的基质。或者，类固醇可以与具有一个或多个开口有效以允许类固醇释放到外部环境中的聚合物涂层相关联。植入物可以放置在眼睛中以治疗一种或多种眼睛状况。类固醇从植入物中释放超过约两个月，可能会释放超过几年。

32. 发明申请

WO2005072701A1 COMPOSITIONS FOR LOCALIZED THERAPY OF THE EYE, COMPRISING PREFERABLY TRIAMCINOLONE ACETONIDE AND HYALURONIC ACID 审中-公开
标题翻译：用于局部化治疗眼睛的组合物，包含优选的三羟甲基柠檬酸三乙酯和羟丙酸
公开(公告)号：WO2005072701A1
公开(公告)日：2005-08-11
申请号：PCT/US2005/001371
申请日：2005-01-14
申请人： ALLERGAN, INC. , HUGHES, Patrick, M. , OLEJNIK, Orest , WHITCUP, Scott, M. , BURKE, James, A.
发明人： HUGHES, Patrick, M. , OLEJNIK, Orest , WHITCUP, Scott, M. , BURKE, James, A.
IPC分类号： A61K9/00
CPC分类号： A61K38/13 , A61K9/0048 , A61K9/0051 , A61K9/10 , A61K9/14 , A61K31/00 , A61K47/36 , Y10S514/912
摘要： Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.
摘要翻译：提供了组合物和使用这种组合物的方法，其可用于注射到人或动物眼睛的后段中。这样的组合物包括促进在眼睛的视网膜色素上皮中形成治疗剂的浓缩区域的难溶性治疗剂的小颗粒。通过将治疗剂与眼科可接受的聚合物组分组合来形成颗粒。颗粒具有小于约3000纳米的尺寸，并且在一些情况下小于约200纳米。组合物的一个实例包括曲安奈德的颗粒和透明质酸的尺寸小于约3000纳米。

33. 发明申请

WO2004087098A2 PRESERVED OPHTHALMIC COMPOSITIONS 审中-公开
标题翻译：保留的眼科组合物
公开(公告)号：WO2004087098A2
公开(公告)日：2004-10-14
申请号：PCT/US2004/008913
申请日：2004-03-23
申请人： ALLERGAN, INC. , CHANG, James, N. , GRAHAM, Richard , OLEJNIK, Orest , HUTH, Stanley, W. , LUU, Michelle
发明人： CHANG, James, N. , GRAHAM, Richard , OLEJNIK, Orest , HUTH, Stanley, W. , LUU, Michelle
IPC分类号： A61K9/00
CPC分类号： A61K31/498 , A61K9/0048 , A61K33/14 , A61K2300/00
摘要： Ophthalmic compositions include a carrier component, an oxy-chloro component present at an amount effective in preserving the composition, and at least one additional component, e.g. a borate component and/or a glycerin component present in an amount effective to enhance a preservative efficacy of the composition. The compositions preferably also include one or more other components, such as therapeutic components, e.g., quinoxaline components, and polyanionic components effective to provide the compositions with one or more functionalities.
摘要翻译：眼科组合物包括载体组分，以有效保护组合物的量存在的氧 - 氯组分和至少一种另外的组分，例如，以有效提高组合物的防腐功效的量存在的硼酸盐组分和/或甘油组分。组合物优选还包括一种或多种其它组分，例如治疗成分，例如喹喔啉组分，以及有效提供组合物一种或多种功能的聚阴离子组分。

34. 发明申请

WO1995031211A1 LACRIMAL GLAND SPECIFIC EMULSIONS FOR TOPICAL APPLICATION TO OCULAR TISSUE 审中-公开
标题翻译： LACRIMAL GLAND特异性乳剂用于局部应用于眼科组织
公开(公告)号：WO1995031211A1
公开(公告)日：1995-11-23
申请号：PCT/US1995006302
申请日：1995-05-17
申请人： ALLERGAN, INC. , DING, Shulin , TIEN, Walter, L. , OLEJNIK, Orest
发明人： ALLERGAN, INC.
IPC分类号： A61K38/13
CPC分类号： A61K9/0048 , A61K38/13 , Y10S514/912 , Y10S514/941 , Y10S514/943 , Y10S514/975
摘要： A pharmaceutical composition is disclosed in the form of a nonirrtating emulsion which includes at least one cyclosporin in admixture with a higher fatty acid glyceride and polysorbate 80. More particularly, the cyclosporin may be cyclosporing A and the higher fatty acid glyceride may be castor oil. Composition has been found to be of a high comfort level and low irritation potential suitable for delivery of medications to sensitive areas such as ocular tissues with enhanced absorption in the lacrimal gland. In addition, the composition has stability for up to nine months without crystallization of cyclosporin.
摘要翻译：公开了一种无水乳剂形式的药物组合物，其包括与高级脂肪酸甘油酯和聚山梨醇酯80混合的至少一种环孢菌素。更具体地，环孢菌素可以是环孢菌素A，高级脂肪酸甘油酯可以是蓖麻油。已经发现组合物具有高舒适度和低刺激潜能，适用于将药物递送至敏感区域，例如泪腺增强吸收的眼组织。此外，组合物在不结晶环孢菌素的情况下稳定长达九个月。

35. 发明申请

WO1995013050A1 OPHTHALMIC FORMULATION USEFUL IN THE TREATMENT OF DRY EYE SYNDROM 审中-公开
标题翻译：眼科配方
公开(公告)号：WO1995013050A1
公开(公告)日：1995-05-18
申请号：PCT/EP1994003607
申请日：1994-11-03
申请人： CIBA-GEIGY AG , OLEJNIK, Orest , WENDEL, Fred, W.
发明人： CIBA-GEIGY AG
IPC分类号： A61K09/00
CPC分类号： A61K9/0048
摘要： A preservative-free ophthalmic composition is disclosed which is useful in the treatment of conditions such as dry eye and which comprises an aqueous solution of (a) about 0.20 to 2.5 weight percent of a polymer selected form the group consisting of hydroxyalkyl cellulosics and polyalkylene glycols; (b) a non-ionic tonicity adjusting agent selected from the group consisting of mannitol, sorbitol, dextrose, sucrose, urea, glycerol, and mixtures thereof, in a amount sufficient to generate a tonicity of about 50 to 350 milliosmols per kilogram (mOsmol/kg); (c) an ionic salt which is preferably an alkali metal halide, in an amount sufficient to approximate the salt concentration of the human tear fluid; and (d) an antimicrobial in an amount sufficient to generate sufficient borate to maintain or reduce microbial concentrations for a period of 12 hours to 72 hours.
摘要翻译：公开了一种无防腐剂的眼用组合物，其可用于治疗诸如干眼症的病症，并且其包含（a）约0.20至2.5重量％的选自羟烷基纤维素和聚亚烷基二醇的聚合物的水溶液 ; （b）选自甘露醇，山梨糖醇，葡萄糖，蔗糖，尿素，甘油及其混合物的非离子张力调节剂，其量足以产生约50至350毫摩尔/千克的张力（mOsmol /公斤）; （c）优选碱金属卤化物的离子盐，其量足以接近人类泪液的盐浓度; 和（d）足以产生足够的硼酸盐以在12小时至72小时期间维持或减少微生物浓度的量的抗微生物剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式